75 patients affected by knee OA were assessed for eligibility and 72 were enrolled and randomized to receive either intra-articular polynucleotides ( Condrotide-36 patients ) or hyaluronic acid ( Hyalubrix-36 patients ) at the Orthopedic Institute `` Gaetano Pini '' ( Milan ) .